drugset
drugset / Trial / NCT06397313

RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis

NCT06397313 ↗

Phase 2 Recruiting 230 enrolled Ryvu Therapeutics SA
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The objective of this clinical trial is to evaluate the efficacy (how well the drug works), safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the study drug, RVU120, in treating adult patients with intermediate or high-risk, primary or secondary myelofibrosis. RVU120 will be given as a single agent or in combination with ruxolitinib.

Timeline

Start
2024-09-19
Primary completion
2026-06
Completion
2027-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ruxolitinib Small molecule — Oral
Subject SEL-120 FREE BASE Small molecule 250 mg —

Indications

myelofibrosis